Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib With Endocrine Therapy and Palbociclib vs Endocrine Therapy and Ribociclib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer

NCT06757634 is registered in ClinicalTrials.gov with Celcuity Inc as lead sponsor.

NCT NCT06757634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06757634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib With Endocrine Therapy and Palbociclib vs Endocrine Therapy and Ribociclib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer
Lead sponsor
Celcuity Inc
Phase
Phase 3
Overall status
Recruiting
Start date
July 24, 2025
Completion date
July 30, 2033
Enrollment
1,180 (estimated)
Sites
239

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer